ClinicalTrials.gg
RecruitingNCT04573660AV-MDRUpdated Oct 13, 2026

Abbott Vascular Medical Device Registry

An observational study in Acute Myocardial Infarction, Restenoses, Coronary and Coronary Artery Lesions, sponsored by Abbott Medical Devices. Recruiting at 37 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

How we know

From the registry’s dates

  • Started Oct 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,784
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Coronary Restenosis by Abbott — 1 open to participants now, 1 under way, none of them phase 3. Coronary Restenosis · Abbott.

Planned enrollment
3rd of 14
3,784 · median 1,483
Started
2020
the only one that year
Observational
14 of 39
1 open now
Registered
39th of 39
by date

Among the 39 studies in Coronary Restenosis by Abbott, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is the only one that started in 2020, is one of 14 observational ones, and was the 39th registered.

Coronary Restenosis

107 studies on the registry are indexed under Coronary Restenosis; 10 are open to participants now.

Browse Coronary Restenosis studies →

Open to participants now

1 of the 39 studies in Coronary Restenosis by Abbott is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 8 Coronary Restenosis studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Coronary Restenosis by Abbott, or all of them as a file.
02

Study summary

The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.

03

Conditions studied

  • Acute Myocardial Infarction
  • Restenoses, Coronary
  • Coronary Artery Lesions
  • Venous Embolism
  • Arterial Embolism

Keywords

  • Coronary and peripheral stents
  • ABT-CIP-10349
  • Vascular plugs
  • Pacing catheters
  • Measurement and imaging (FFR and OCT)
  • Peripheral dilatation catheters
  • Coronary dilatation catheters
  • Coronary and peripheral guidewires
  • Vessel closure/compression devices
  • Vascular access introducers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll subjects 18 years and older of all genders in which at least one Abbott target device specified in the CIP is used. Outcomes will be collected on any ancillary devices in scope, but patients will not be enrolled for use of an ancillary device without treatment with any target device. Patients must meet all general eligibility criteria and provide written informed consent or be enrolled under an IRB/EC approved waiver of consent, prior to sites' collection of patient data for the investigation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is at least 18 years of age.
  2. Subject has a planned procedure, or underwent a procedure, that will use/used one or more Abbott target devices covered in this registry.
  3. Subject is willing and able to comply with, or has already completed, the follow-up schedule specified in this protocol.
  4. Subject must provide written prior to any clinical investigation-related data collection or be enrolled under an IRB/EC approved waiver of consent.

Exclusion criteria

Exclusion Criteria:

1. Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months of the date of procedure.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,784 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coronary and peripheral stents

    Participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents

    Device: Coronary and peripheral stents

  • Pacing catheters

    Participants in the Pacing catheters arm will receive Pacing catheters

    Device: Pacing catheters

  • Vascular plugs

    Participants in the Vascular plugs arm will receive Vascular plugs

    Device: Vascular plugs

  • Measurement and imaging (FFR and OCT)

    Participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)

    Device: Measurement and imaging (FFR and OCT)

  • Peripheral dilatation catheters

    Participants in the Peripheral dilatation catheters arm will receive Peripheral dilatation catheters

    Device: Peripheral dilatation catheters

  • Coronary dilatation catheters

    Participants in the Coronary dilatation catheters arm will receive Coronary dilatation catheters

    Device: Coronary dilatation catheters

  • Coronary and peripheral guidewires

    Participants in the Coronary and peripheral guidewires arm will receive Coronary and peripheral guidewires

    Device: Coronary and peripheral guidewires

  • Vessel closure/compression devices

    Participants in the Vessel closure/compression devices arm will receive Vessel closure/compression devices

    Device: Vessel closure/compression devices

  • Vascular access introducers

    Participants in the Vascular access introducers devices arm will receive Vascular access introducers

    Device: Vascular access introducers

Interventions

  • DeviceCoronary and peripheral stents

    The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents

  • DevicePacing catheters

    The participants in the Pacing catheters arm will receive Pacing catheters

  • DeviceVascular plugs

    The participants in the Vascular plugs arm will receive Vascular plugs

  • DeviceMeasurement and imaging (FFR and OCT)

    The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)

  • DevicePeripheral dilatation catheters

    The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters

  • DeviceCoronary dilatation catheters

    The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters

  • DeviceCoronary and peripheral guidewires

    The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires

  • DeviceVessel closure/compression devices

    The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices

  • DeviceVascular access introducers

    The participants in the Vascular access introducers arm will receive Vascular access introducers

06

What researchers measure

Primary outcomes

  1. Coronary Stents - Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)

    Composite of all-cause death, MI or target lesion revascularization (TLR) will be assessed among the patients who receive Coronary Stents.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  2. Coronary Stents - Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)

    Composite of all-cause death, MI or target lesion revascularization (TLR) will be assessed among the patients who receive Coronary Stents.

    Time frame: 30 days

  3. Coronary Stents - Number of participants with composite of all-cause death, MI or target lesion revascularization (TLR)

    Composite of all-cause death, MI or target lesion revascularization (TLR) will be assessed among the patients who receive Coronary Stents.

    Time frame: 12 months

  4. Peripheral Stents - Number of participants with composite of all-cause death, amputation, and TLR

    Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive Peripheral Stents.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  5. Peripheral Stents - Number of participants with composite of all-cause death, amputation, and TLR

    Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive Peripheral Stents.

    Time frame: 30 days

  6. Peripheral Stents - Number of participants with composite of all-cause death, amputation, and TLR

    Composite of all-cause death, amputation, and TLR will be assessed among the patients who receive Peripheral Stents.

    Time frame: 12 months

  7. Peripheral Stents (Renal Indication) - Number of participants with composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR

    Composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR will be assessed among the patients who receive Peripheral Stents (Renal Indication).

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  8. Peripheral Stents (Renal Indication) - Number of participants with composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR

    Composite of all-cause death, ipsilateral nephrectomy, Embolic events resulting in kidney damage or TLR will be assessed among the patients who receive Peripheral Stents (Renal Indication).

    Time frame: 30 days

  9. Peripheral Stents (Renal Indication) - Number of participants with composite of TLR

    Composite of TLR will be assessed among the patients who receive Peripheral Stents (Renal Indication).

    Time frame: 12 months

  10. Pacing Catheters - Number of participants with composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation)

    Composite of potential complications (venous thrombosis, pulmonary emboli, arrhythmias, perforation) will be assessed among the patients who receive Pacing Catheters.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  11. Pacing Catheters - Loss of capture (assessed based on physiological parameter-ECG)

    Loss of capture (average time of loss of capture across patients) will be assessed among the patients who receive Pacing Catheters. ECG is used to measure whether the pacing device stimulates the heart. Absence of a stimulation is considered a loss of capture.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  12. Vascular Plugs - Number of participants with composite of potential complications (Implant success, occlusion success, migration)

    Composite of potential complications including implant success, occlusion success, migration will be assessed among the patients who receive Vascular Plugs.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  13. Vascular Plugs - Number of participants with composite of occlusion success and migration

    Composite of occlusion success and migration will be assessed among the patients who receive Vascular Plugs.

    Time frame: 30 days

  14. Fractional flow reserve - Number of participants with composite of vessel dissection, perforation, and thromboembolism

    Composite of vessel dissection, perforation, and thromboembolism during procedure will be assessed among the patients who receive Fractional flow reserve (FFR).

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  15. Fractional flow reserve - Number of participants with signal drift (Signal drift between measurements (Pd/Pa** pressure drift >0.03; <0.97 or >1.03)

    Signal drift (Signal drift between measurements (Pd/Pa\*\* pressure drift \>0.03; \<0.97 or \>1.03) will be assessed among the patients who receive FFR.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  16. Optical Coherence Tomography Products - Number of participants with Intraprocedural complications (number of dissections ≥type B, slow flow or no reflow, thrombus, abrupt closure, perforation)

    Intraprocedural complications will be assessed among the patients who receive Optical Coherence Tomography (OCT).

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  17. Optical Coherence Tomography Products - Number of participants with Successful crossing and image quality pre-PCI

    Successful crossing and image quality pre- PCI will be assessed among the patients who receive OCT.

    Time frame: During procedure - Before the stent is implanted (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  18. Optical Coherence Tomography Products - Number of participants with Successful crossing and image quality post-PCI

    Successful crossing and image quality post-PCI will be assessed among the patients who receive OCT.

    Time frame: During procedure - Between 10-30 minutes post-PCI (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  19. Peripheral Dilatation Catheters - Number of participants with Composite of major adverse events

    Composite of major adverse events (e.g., distal embolization, dissection, perforation, amputation primary to balloon usage, total occlusion, abrupt closure, renal failure primary to balloon usage will be assessed among the patients who receive Peripheral Dilatation Catheters.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  20. Peripheral Dilatation Catheters - Number of participants with Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) (assessed based on physiological parameters)

    Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) will be assessed among the patients who receive Peripheral Dilatation Catheters. Device success can be summarized as the successful treatment with the device.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  21. Coronary Guidewires - Number of participants with Composite of major adverse events

    Composite of major adverse events (e.g., vessel perforation, dissection, occlusion, embolism) will be assessed among the patients who receive Coronary Guidewires.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  22. Coronary Guidewires - Number of participants with Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion) (assessed based on physiological parameters)

    Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion will be assessed among the patients who receive Coronary Guidewires. Device success can be summarized as the successful treatment with the device.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  23. Peripheral Guidewires - Number of participants with Composite of major adverse events

    Composite of major adverse events (e.g., vessel perforation, dissection, occlusion, embolism) will be assessed among the patients who receive Peripheral Guidewires.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  24. Peripheral Guidewires - Number of participants with Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion) (assessed based on physiological parameters)

    Device success (Successfully placed, Successfully introduce/position diagnostic/interventional device, Successfully reach/cross target lesion will be assessed among the patients who receive Peripheral Guidewires. Device success can be summarized as the successful treatment with the device.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  25. Coronary Dilatation Catheters - Number of participants with Composite of major adverse events

    Composite of major adverse events (e.g., distal embolization, dissection, perforation, amputation primary to balloon usage, total occlusion, abrupt closure, renal failure primary to balloon usage will be assessed among the patients who receive Coronary Dilatation Catheters.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  26. Coronary Dilatation Catheters - Number of participants with Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) (assessed based on physiological parameters)

    Device success (Successful delivery, Successful inflation, Successful deflation, Successful withdrawal) will be assessed among the patients who receive Coronary Dilatation Catheters. Device success can be summarized as the successful treatment with the device.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  27. Vessel Closure Devices - Number of participants with Composite of access complications

    Composite of access complications (e.g., hematoma, stenosis/occlusion, infection, access site bleeding) will be assessed among the patients who receive Vessel Closure Devices.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  28. Vessel Closure Devices - Number of participants with Successful hemostasis Major and minor bleeding

    Successful hemostasis Major and minor bleeding will be assessed among the patients who receive Vessel Closure Devices.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  29. Vessel Compression Devices - Number of participants with Major and minor bleeding

    Major and minor bleeding will be assessed among the patients who receive Vessel Compression Devices.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  30. Vessel Compression Devices - Number of participants with Complications including: pseudoaneurysm, hematoma (>5cm) in diameter, Hb drop>20 g/L, extended compression time >6 hours, blood transfusion required, bleeding requiring surgical procedure

    Complications including: pseudoaneurysm requiring treatment, hematoma (\>5cm) in diameter, Hb drop\>20 g/L, extended compression time \>6 hours, blood transfusion required, bleeding requiring surgical procedure will be assessed among the patients who receive Vessel Compression Devices.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  31. Vascular Access Introducers - Incidence of safety issues

    Incidence of safety issues (e.g., bleeding, air embolism, hematoma, vessel damage (dissection, perforation, pseudoaneurysm), infection, thrombosis, AV fistula, occlusion, radial artery spasm) will be assessed among the patients who receive Vascular Access Introducers.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

  32. Vascular Access Introducers - Incidence of performance issues

    Incidence of performance issues (e.g., unable to introduce other devices, failure to maintain hemostasis valve integrity, air leakage, bending or kinking of introducer, difficulty inserting/removing the sheath, device breakage detachment or separation, issue with an associated accessory) will be assessed among the patients who receive Vascular Access Introducers.

    Time frame: During procedure (Start of procedure: defined as time a guidewire first enters the vasculature. End of procedure: defined as vessel closure following the index procedure)

07

Study locations

34 of 37 sites recruiting
  • University Hospital - Univ. of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35249, United States
    Recruiting
    • Dr. Mustafa Ahmed · Principal investigator
  • Arkansas Heart Hospital
    Little Rock, Arkansas 72211, United States
    Recruiting
    • Vijay Raja, M.D. · Principal investigator
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
    Recruiting
    • Somjot Brar, MD · Principal investigator
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
    Recruiting
    • James D Flaherty, MD · Principal investigator
  • Bryan Heart
    Lincoln, Nebraska 68506, United States
    Recruiting
    • Brock Cookman, M.D. · Principal investigator
  • Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
    • Richard Gumina, M.D. · Principal investigator
  • Wellmont CVA Heart Institute
    Kingsport, Tennessee 37660, United States
    Recruiting
    • Gaurav Rana, MD · Principal investigator
  • Perth Institute of Vascular Research
    Nedlands, WAUS 6009, Australia
    Recruiting
    • Bibombe Patrice Mwipatayi · Principal investigator
  • Sir Charles Gairdner Hospital
    Nedlands, WAUS 6009, Australia
    Recruiting
    • Carolina Bravo Ceballos · Principal investigator
  • Universitätsklinik Graz
    Graz, Styria 8036, Austria
    Recruiting
    • Hannes Deutschmann · Principal investigator
  • Onze-Lieve-Vrouwziekenhuis Campus Aalst
    Aalst, Eflndrs 9300, Belgium
    Recruiting
    • Lieven Maene · Principal investigator
  • AZ Sint-Blasius Ziekenhuis
    Dendermonde, Eflndrs 9200, Belgium
    Recruiting
    • Koen Deloose · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Recruiting
    • Jianfeng Han · Principal investigator
  • Jinhua Municipal Central Hospital
    Jinhua, Zhejian 321000, China
    Recruiting
    • Fengfeng Jiang, M.D. · Principal investigator
  • Ningbo First Hospital
    Ningbo, Zhejian 315000, China
    Recruiting
    • Zhiqing Lin · Principal investigator
  • CH Chartres
    Chartres, Centre-Val de Loire 28018, France
    Recruiting
    • Radwane Hakim · Principal investigator
  • Hôpital Paris Saint-Joseph
    Paris, Ile 75014, France
    Completed

    Not enrolling at this site — choose another above.

  • Cardioangiologisches Centrum am Bethanien Krankenhaus
    Frankfurt am Main, Hesse 60389, Germany
    Recruiting
    • Michael Piorkowski · Principal investigator
  • UNIVERSITATSMEDIZIN der Johannes Gutenberg-Universität Mainz
    Mainz, Rhinela 55131, Germany
    Recruiting
    • Prof. Dr. med. Christine Espinola-Klein · Principal investigator
  • Universitätsklinikum Leipzig AÖR
    Leipzig, Saxony 04103, Germany
    Recruiting
    • Prof. Dr. med. Dierk Scheinert · Principal investigator
  • Herz- u. Gefäßzentrum Bad Bevensen
    Bad Bevensen, Saxon 29549, Germany
    Recruiting
    • Wulf Euringer · Principal investigator
  • Universitätsklinikum Schleswig-Holstein Campus Kiel
    Kiel, Schlesw 24105, Germany
    Recruiting
    • Dr. Matthias Lutz · Principal investigator
  • Semmelweis University
    Budapest, Budapest 1122, Hungary
    Recruiting
    • Bela Merkely · Principal investigator
  • Ospedale San Raffaele
    Milan, Lombard 20132, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Centro Cardiologico Monzino
    Milan, Lombard 20138, Italy
    Recruiting
    • Doctor Galli · Principal investigator
  • Policlinico San Donato
    San Donato Milanese, Lombard 20097, Italy
    Recruiting
    • Francesco Bedogni, MD · Contact
  • St. Antonius Ziekenhuis
    Nieuwegein, Utrecht 3435 CM, Netherlands
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitari Vall d'Hebron
    Barcelona, Catalon 08035, Spain
    Recruiting
    • Sergi Bellmunt · Principal investigator
  • Hospital Universitario de la Paz
    Madrid, Madrid 28046, Spain
    Recruiting
    • Raul Moreno · Principal investigator
  • Hospital General Universitario de Alicante
    Alicante, Valncia 03010, Spain
    Recruiting
    • Javier Irurzun · Principal investigator
  • Kantonsspital Aarau
    Aarau, Basel 5001, Switzerland
    Recruiting
    • Hans Martin Gissler · Principal investigator
  • Inselspital - University Hospital of Bern
    Bern, Canton of Bern 3010, Switzerland
    Recruiting
    • Marc Schindewolf, M.D. · Principal investigator
  • Taichung Veterans General Hospital
    Taichung, Mtaiwan 40705, Taiwan
    Recruiting
    • Wen Lieng Lee · Principal investigator
  • Cathay General Hospital
    Taipei, Ntaiwan 106, Taiwan
    Recruiting
    • Chi-Hung Huang · Principal investigator
  • National Cheng Kung University Hospital
    Tainan, Staiwan 704, Taiwan
    Recruiting
    • Ju-Yi Chen · Principal investigator
  • Chi Mei Hospital
    Tainan, Staiwan 710, Taiwan
    Recruiting
    • Zhih-Cherng Chen · Principal investigator
  • Al Qassimi Hospital
    Sharjah city, Emirate of Sharjah 3500, United Arab Emirates
    Recruiting
    • Arif Al Nooryani · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2020 (actual). Primary completion is estimated for Nov 2030, 121 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Oct 5, 2020
StartActual
Oct 25, 2020
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04573660
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Oct 25, 2020
Primary completion
Nov 2030 (estimated)
Completion
Nov 2031 (estimated)
Last update
Oct 13, 2026

Study contacts

Sharan Dhanjal, MPH
Contact
sharanjeet.dhanjal@abbott.com
+1 714-926-8292
Chinedu Agbonghai, MS
Contact
chinedu.agbonghai@abbott.com
Chananit Hutson, PhD
study director · Abbott Medical Devices

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion